Evidence map›Paper›PMID 39528988›Full record

ArticleBMC infectious diseases2024

COVID-19 inflammatory signature in a Mozambican cohort: unchanged red blood series and reduced levels of IL-6 and other proinflammatory cytokines.

Vânia Maphossa, Onélia Guiliche, Teresa Babetine, Celso Castiano, Osvaldo Inlamea, Marino Marengue, Igor Capitine, Lúcia Chambal, Almiro Tivane, Jahit Sacarlal and 2 more

Abstract read
In one paragraph

Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vânia Maphossa *Instituto Nacional de Saúde, Maputo, Mozambique. vania.maphossa@ins.gov.mz.
Onélia Guiliche *Instituto Nacional de Saúde, Maputo, Mozambique.
Teresa BabetineInstituto Nacional de Saúde, Maputo, Mozambique.
Celso CastianoInstituto Nacional de Saúde, Maputo, Mozambique.
Osvaldo InlameaInstituto Nacional de Saúde, Maputo, Mozambique.
Marino MarengueHospital Geral do Polana Caniço, Maputo, Mozambique.
Igor CapitineInstituto Nacional de Saúde, Maputo, Mozambique.
Lúcia ChambalFaculdade de Medicina, Universidade Eduardo Mondlane, Maputo, Mozambique.
Almiro TivaneInstituto Nacional de Saúde, Maputo, Mozambique.
Jahit SacarlalFaculdade de Medicina, Universidade Eduardo Mondlane, Maputo, Mozambique.
Eugênia Terra-GranadoCentro de Pesquisas, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
Raquel Matavele ChissumbaInstituto Nacional de Saúde, Maputo, Mozambique. raquelmatavele@gmail.com.

Funding

Pitt-Mozambique Training Program (Pitt-MozHRTP) in SARS-CoV-2, Cardiovascular Disease, and Diabetes in People with HIVD43TW011827 · FIC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Lee H Harrison, JEAN BISIMWA NACHEGA · 2022 to 2026
$1.2M
University of Pittsburgh HIV-Comorbidities Research Training Program in South AfricaD43TW010937 · FIC · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NACHEGA, JEAN BISIMWA, SEEDAT, SORAYA · 2019 to 2023
$1.2M
a Fogarty International Center HIV Research Training Program grant, National Institutes of Health, to the University of Pittsburgh and Stellenbosch University D43TW010937FIC NIH HHS D43 TW010937FIC NIH HHS D43 TW011827Organization for Women in Science for the Developing World (OWSD) 4500429473
6 · The paper itself

Abstract

backgroundAlterations in haematological, biochemical parameters and cytokine levels, were reported in patients with COVID-19, however, there is an underrepresentation of the African population, which could provide evidence for understanding SARS-CoV-2 pathogenesis and useful tools for clinical management of cases. In this study, we aimed to determine the haematological, biochemical and cytokine profile in Mozambican individuals with SARS-CoV-2.

methodsA cohort of 85 Mozambican individuals with RT-PCR SARS-CoV-2 results, was stratified into negative, asymptomatic, mild, moderate, and severe categories. Haematological, biochemical and cytokines measurement were performed on samples from the study participants. Principal component analysis (PCA) was performed to identify similar patterns among the study cases. Comparisons between groups were performed using the Kruskal-Wallis test. Receiver operating characteristic (ROC) and area under the curve (AUC) analysis were conducted to evaluate the ability of these parameters to distinguish severe from non-severe cases of SARS-CoV-2 infection.

resultsSARS-CoV-2 infection was associated with a significant (p < 0.05) decrease in peripheral blood absolute counts of total lymphocytes and eosinophils, below the reference values along with no abnormal change (p > 0.05) in red blood cell count, haemoglobin, platelets and other red series parameters. At the serum level, SARS-CoV-2 infection was associated with an increase in serum levels of C-reactive protein (C-RP) and glucose above the reference values and to a significant reduction a significant (p < 0.05) reduction in levels of interferon-gamma (INF-γ), Tumour Necrosis Factor alfa (TNF-α) and the interleukin 1 beta (IL-1β) and IL-6 in severe cases, when compared to negative cases. Haematological, biochemical and cytokine profiles segregate severe from non-severe cases of COVID-19 with an excellent performance of C-RP (AUC = 0.95; p < 0.001) and good performance of lymphocytes (AUC = 0.88; p < 0.001) and IL-15 (AUC = 0.86; p < 0.001).

conclusionThe lack of variation in red and platelet series, coupled with a decrease in the levels of classical pro-inflammatory in severe cases, deviates from what has been reported in other contexts suggesting, that there may be peculiarities in COVID-19 manifestation within the context of this study population. Furthermore, these results identify parameters with potential for clinical management of COVID-19 and therefore good resource allocation, particularly for severe cases.

Indexed as

COVID-19CytokinesInterleukin-6SARS-CoV-2AdultCohort StudiesErythrocytesFemaleHumansInflammationMaleMiddle AgedMozambiqueYoung AdultCytokinesIL6 protein, humanInterleukin-6BiochemistryCOVID-19CytokinesHaematologyImmunological signatureSARS-CoV-2

Identifiers

PMID39528988
PMCPMC11555969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.